Immunohistochemistry

immunohistochemistry

Off-the-shelf Immuno- histochemistry assays

  • OncoDNA embraces the challenges and benefits of IHC. Our molecular pathology experts come from extensive clinical pathology and research-based backgrounds.

 

  • So the IHC assays available in our portfolio can serve cancer diagnostic and cancer theranostic, question the potential benefit of different treatment approaches (Chemo, targeted therapy, immunotherapy).
    • Cancer diagnostic : ER, PR, CD117, CD10, CKs, …
    • Chemo potential benefit : TLE3, TOPO1, RRM1, TUBB3, TOP2A, …
    • Targeted therapies benefit : EGFR, VEGFR2, HER2, PTEN, …
    • Immuno therapies benefit : PD-L1, CD8, …

 

  • Immunohistochemistry assays are also great tools to question activation of some cancer pathways in cancer cells: mTOR pathway, MAPK pathway, cell cycle pathway, … we have validated IHC and pIHC assays to question those pathways
    • Cancer pathways : p4EBP1, pERK1/2, cMET, pAKT, pRB, CDK4, …

On-demand Immuno- histochemistry assays

Beside the large portfolio of off-the-shelf IHCs assays, OncoDNA has developed a large expertise in IHC based biomarker assay development and validation services. Developed assays can be used from preclinical development through proof of concept to testing in clinical trials, ensuring transition of procedures and technology during the drug development process.

ihc_image
Download IHC panel

A question about Immunohistochemistry?